

## ATAGENIX LABORATORIES

# Catalog Number:ATMA10056Mo Anti PDL1 mouse monoclonal antibody

### 产品概述

产品名(Product Name) Anti PDL1 mouse monoclonal antibody

货号 ( Catalog No. ) ATMA10056Mo

种类 ( Category ) Primary antibody

宿主 ( Host ) Mouse

反应种属 ( Species specificity ) Homo sapiens (Human)

应用实验(Tested applications) Elisa,WB,flow,IHC

**克隆性 ( Clonality )** Monoclonal

**克隆编号 (Clone No.)** 130-A-5

**偶连物(Conjugation**) Unconjugate

免疫原 (Immunogen ) humna PDL1 DNA sequence

别名 B7-H1; CD274; Programmed death ligand 1

Uniprot ID Q9NZQ7

产品性能

状态 (Form ) Liquid

储存溶液 (Buffer) PBS, pH7.4, containing 0.05% proclin300, 50% glycerol.

存放条件 (Storage) Use a manual defrost freezer and avoid repeated freeze thaw cycles.

Store at 4 °C for frequent use.

Store at -20 to -80 °C for twelve months from the date of receipt.

浓度(Concentration) 1mg/ml

亚型 (Isotype) IgG1

分子量 (MW) 34 kDa

纯化方式 ( Purity ) Protein G purified from mice ascites

应用

Elisa:1:1000~5000;WB:1:1000~4000;Flow:1:100~200,IHC:1:50~100

#### 产品背景



## ATAGENIX LABORATORIES

# Catalog Number:ATMA10056Mo Anti PDL1 mouse monoclonal antibody

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed: 28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.